Rationale The risk of recurrent ischemia is high in the acute period after ischemic stroke and
transient ischemic attack. Aspirin is recommended by guidelines for this indication, but more …

Background: Patients with minor acute ischemic stroke or transient ischemic attack are at
high risk for subsequent stroke, and more potent antiplatelet therapy in the acute setting is …

Background and Purpose—SOCRATES (Acute Stroke or Transient Ischemic Attack Treated
With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor with aspirin in …

Background Ticagrelor is an effective antiplatelet therapy for patients with coronary
atherosclerotic disease and might be more effective than aspirin in preventing recurrent …

Rationale In patients with acute cerebral ischemia, the rate of stroke, myocardial infarction,
or death during 90 days was reported to be non-significantly lower with ticagrelor compared …

Background Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after
an ischemic stroke or transient ischemic attack (TIA). In a previous trial, ticagrelor was not …

Background Ticagrelor may be a more effective antiplatelet therapy than aspirin for the
prevention of recurrent stroke and cardiovascular events in patients with acute cerebral …

Background and Purpose: In patients with acute mild-moderate ischemic stroke or high-risk
transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack …

Background and Purpose—In the SOCRATES trial (Acute Stroke or Transient Ischemic
Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), ticagrelor was not superior …

Background and Objectives The goal of this work was to investigate the short-term time-
course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or …